Lördag 13 September | 21:35:09 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Biosergen’s CEO on the preparations for the next clinical phase
2025-08-21 09:52:00

2025 is shaping up to be a defining year for Biosergen, the antifungal drug developer with a mission to combat life-threatening fungal infections. During the second quarter, the biotech company has advanced its clinical program for BSG005, made key leadership appointments, and laid out the next steps toward pivotal studies. We contacted CEO Tine Olesen to learn more about what lies ahead.

Read the full interview at biostock.se:

https://biostock.se/en/2025/08/biosergens-ceo-on-the-preparations-for-the-next-clinical-phase/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden